APA

Matsuda Y., Narita S., Nara T., Mingguo H., Sato H., Koizumi A., Kanda S., Numakura K., Saito M., Inoue T., Hiroshima Y., Nanjo H., Satoh S., Tsuchiya N. & Habuchi T. (20201218). Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer. : BMC cancer.

Chicago

Matsuda Yoshinori, Narita Shintaro, Nara Taketoshi, Mingguo Huang, Sato Hiromi, Koizumi Atsushi, Kanda Sohei, Numakura Kazuyuki, Saito Mitsuru, Inoue Takamitsu, Hiroshima Yuko, Nanjo Hiroshi, Satoh Shigeru, Tsuchiya Norihiko and Habuchi Tomonori. 20201218. Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer. : BMC cancer.

Harvard

Matsuda Y., Narita S., Nara T., Mingguo H., Sato H., Koizumi A., Kanda S., Numakura K., Saito M., Inoue T., Hiroshima Y., Nanjo H., Satoh S., Tsuchiya N. and Habuchi T. (20201218). Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer. : BMC cancer.

MLA

Matsuda Yoshinori, Narita Shintaro, Nara Taketoshi, Mingguo Huang, Sato Hiromi, Koizumi Atsushi, Kanda Sohei, Numakura Kazuyuki, Saito Mitsuru, Inoue Takamitsu, Hiroshima Yuko, Nanjo Hiroshi, Satoh Shigeru, Tsuchiya Norihiko and Habuchi Tomonori. Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer. : BMC cancer. 20201218.